Ian Goodwin

Director, Global Program Design, • Fujifilm Diosynth Biotechnologies

Ian Goodwin is a Director in the Viral Gene Therapy Global Program Design team at FUJIFILM Diosynth Biotechnologies (FDB), based in College Station, Texas. He has been at FDB for five years, having also served as Associate Principal Scientist Group Leader in the Process Development group. Ian is currently responsible for providing technical and project scope development support to prospective clients engaged in CDMO selection for viral and non-viral cell & gene therapy products. Ian’s previous experience includes nine years working on the process development and manufacturing of adeno-associated virus (AAV) and lentivirus vectors (LV) in academic, start-up, and CDMO environments. Ian holds a Master’s Degree in Microbiology and Immunology from Drexel University College of Medicine and a B.Sc in Microbiology from The University of Pittsburgh.

Also Speaking

Leila Mekkaoui

Associate Director Synthetic Genomics • Autolus

Tay Salimullah

Vice President, Head of Global Value & Access, Novartis Gene Therapies  • Novartis

Donna Rill

Chief Technical Officer • Triumvira Immunologics

Also Speaking


Post-Event Report

Download the post-event report for Advanced Therapies Week 2023.

Investor List

Take a look at some of the investors who attended Advanced Therapies Week 2023.